Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Free Cash Flow (2016 - 2025)

Editas Medicine (EDIT) has disclosed Free Cash Flow for 11 consecutive years, with -$31.4 million as the latest value for Q3 2025.

  • Quarterly Free Cash Flow rose 48.39% to -$31.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$171.9 million through Sep 2025, up 8.29% year-over-year, with the annual reading at -$210.3 million for FY2024, 58.13% down from the prior year.
  • Free Cash Flow for Q3 2025 was -$31.4 million at Editas Medicine, up from -$50.1 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$19.7 million in Q4 2023, with the low at -$60.8 million in Q3 2024.
  • Average Free Cash Flow over 5 years is -$43.3 million, with a median of -$42.0 million recorded in 2021.
  • The sharpest move saw Free Cash Flow skyrocketed 51.09% in 2023, then plummeted 116.24% in 2024.
  • Over 5 years, Free Cash Flow stood at -$42.0 million in 2021, then increased by 4.15% to -$40.2 million in 2022, then surged by 51.09% to -$19.7 million in 2023, then tumbled by 116.24% to -$42.5 million in 2024, then rose by 26.21% to -$31.4 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$31.4 million, -$50.1 million, and -$47.9 million for Q3 2025, Q2 2025, and Q1 2025 respectively.